Stock listing

NASDAQ:TCRX TScan Therapeutics, Inc. Stock

Home listing (NASDAQ) of TScan Therapeutics, Inc.

Follow TScan Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TCRX

$0.146 USD -0.003 (-1.7%)

Close on Nov 20, 2026

Past year -85.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.140 – $0.155 USDNov 20, 2026
Volume
391,711 sharesNov 20, 2026
Market cap
$9.27M USDAt the close on Nov 20, 2026 · price × 63.50M shares outstanding
52-week range
$0.140 – $1.470 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$240,184 USDMedian day 559,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
TScan Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TCRX · Home$0.146 USD-0.003 (-1.7%)391,711$0.140$0.155$0.140$0.148Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TCRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.146-0.003-1.7%$0.140$0.155$0.140391,711
$0.148-0.003-1.7%$0.152$0.165$0.142409,284
$0.151+0.006+4.1%$0.145$0.159$0.140309,363
$0.145-0.015-9.7%$0.161$0.168$0.145404,580
$0.161-0.007-4.4%$0.173$0.175$0.160227,684
$0.168-0.018-9.5%$0.183$0.183$0.160714,485
$0.186+0.000+0.2%$0.185$0.190$0.178292,699
$0.185+0.004+2.0%$0.185$0.199$0.175581,570
$0.182-0.006-3.4%$0.190$0.197$0.181669,235
$0.188+0.006+3.4%$0.186$0.189$0.177277,314
$0.182-0.028-13.4%$0.201$0.205$0.171663,603
$0.210+0.021+11.1%$0.198$0.212$0.189640,139
$0.189+0.010+5.5%$0.177$0.195$0.177374,491
$0.179+0.005+2.7%$0.181$0.190$0.175497,329
$0.175-0.020-10.5%$0.193$0.193$0.173333,158
$0.195-0.004-2.0%$0.194$0.197$0.18557,870
$0.199+0.007+3.6%$0.187$0.200$0.183358,909
$0.192+0.002+1.2%$0.190$0.197$0.183539,679
$0.190-0.013-6.6%$0.204$0.204$0.180801,084
$0.203-0.013-6.0%$0.221$0.227$0.202262,800
$0.216-0.008-3.6%$0.215$0.224$0.215299,100
$0.2240.0000.0%$0.220$0.224$0.212688,200
$0.224+0.014+6.7%$0.214$0.234$0.211559,600
$0.210-0.021-9.1%$0.238$0.238$0.210368,300
$0.231-0.008-3.3%$0.238$0.245$0.230568,200
$0.239+0.028+13.3%$0.216$0.243$0.209878,800
$0.211-0.006-2.8%$0.224$0.228$0.201546,600
$0.217-0.021-8.8%$0.240$0.240$0.212461,400
$0.2380.0000.0%$0.240$0.249$0.230483,500
$0.238+0.010+4.4%$0.228$0.247$0.228869,300
$0.228-0.049-17.7%$0.271$0.273$0.2241,534,600
$0.277+0.002+0.7%$0.271$0.283$0.263542,100
$0.275-0.020-6.8%$0.293$0.296$0.264601,900
$0.295-0.026-8.1%$0.317$0.330$0.285749,900
$0.321+0.003+0.9%$0.330$0.330$0.316144,400
$0.318+0.003+1.0%$0.319$0.329$0.311622,700
$0.315-0.003-0.9%$0.322$0.345$0.315554,400
$0.318-0.022-6.5%$0.339$0.346$0.311753,200
$0.3400.0000.0%$0.340$0.348$0.325359,200
$0.340-0.009-2.6%$0.352$0.370$0.330381,900
$0.349-0.015-4.1%$0.369$0.369$0.340606,700
$0.364+0.009+2.5%$0.360$0.372$0.3411,081,000
$0.355+0.024+7.3%$0.333$0.360$0.330918,500
$0.331+0.019+6.1%$0.311$0.342$0.311752,900
$0.312-0.022-6.6%$0.343$0.357$0.3101,143,200
$0.334+0.003+0.9%$0.335$0.362$0.3241,096,300
$0.331+0.010+3.1%$0.330$0.340$0.321883,900
$0.321+0.015+4.9%$0.316$0.322$0.290677,200
$0.306-0.014-4.4%$0.320$0.334$0.3061,104,000
$0.320+0.002+0.6%$0.324$0.325$0.306873,100
$0.318-0.012-3.6%$0.320$0.350$0.310804,600
$0.330-0.015-4.3%$0.340$0.343$0.330704,200
$0.345-0.047-12.0%$0.380$0.380$0.3301,536,300
$0.392+0.021+5.7%$0.370$0.417$0.3651,674,000
$0.371-0.010-2.6%$0.381$0.402$0.3513,091,000
$0.381-0.285-42.8%$0.550$0.570$0.3608,517,400
$0.666-0.064-8.8%$0.723$0.770$0.656820,300
$0.730-0.024-3.2%$0.750$0.766$0.721330,100
$0.754+0.004+0.5%$0.755$0.780$0.750150,700
$0.750-0.027-3.5%$0.777$0.800$0.747287,800
$0.777-0.017-2.1%$0.778$0.792$0.77468,300
$0.794-0.005-0.6%$0.792$0.811$0.777180,600
$0.799+0.019+2.4%$0.790$0.800$0.768194,400
$0.780+0.004+0.5%$0.790$0.790$0.772136,200
$0.776+0.026+3.5%$0.750$0.789$0.750338,300
Ticker
NASDAQ:TCRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All TScan Therapeutics, Inc. news

TScan Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 100 in all · newest Nov 12, 2026 · oldest 2021
Decks
15 decks · latest Sep 2, 2026

Where TScan Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TCRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TCRXBOATSUnited StatesUSD

Valuation

EV/sales −5.9× against a median of 8.6×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$30.80M USD
P/E
Loss
EV/sales
−5.9×
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
−561.6%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.9×
Beta vs S&P 500
1.66

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Alzinova AB · OMXSTO:ALZUS$9.57MUS$8.34Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
CytoMed Therapeutics Limited · NASDAQ:GDTCUS$9.01MUS$8.23Mn/a14.7×n/a2.3×−730.3%0.1×0.16
PreveCeutical Medical Inc · CSE:PREVUS$8.97MUS$8.95Mn/an/an/an/an/an/a0.73
BioLineRX Ltd. · TASE:BLRXUS$8.90MUS$10.13Mn/a8.6×n/a0.5×−171.7%0.3×n/a
Median of the othersUS$9.37MUS$8.65M8.6×0.8×−328.0%0.0×0.69

Forecasts

1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
1.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.79 · 4 analysts
Revenue, year to Dec 2026
3.22M · 3 analysts

Team and board

Officers

OfficerRole
Gavin MacBeathChief Executive Officer
Zoran ZdraveskiChief Legal and Strategy Officer and Secretary
Caileigh DoughertyAVP, Head of Corporate Communications & Investor Relations
Caileigh DoughertyAVPHead of Corporate Communications & Investor Relations
TScan TherapeuticsInvestor Relations
Cagan GurerSenior Vice President, Discovery
Shrikanta ChattopadhyaySenior Vice President, Head of Translational Medicine
Ann HargravesChief Human Resources Officer
Jim MurrayChief Development Operations Officer

Board

DirectorRole
Gavin MacBeathChief Executive Officer
Zoran ZdraveskiChief Legal and Strategy Officer and Secretary

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−9.5%
Q2 2026Aug 12, 2026 · Before open−0.5%
Q1 2026May 6, 2026 · Before open+3.3%
Q4 2025Mar 11, 2026−4.2%
Q3 2025Nov 12, 2025 · Before open−2.5%
Q2 2025Aug 12, 2025 · Before open+3.7%
Q1 2025May 6, 2025 · Before open−9.3%
Q4 2024Mar 5, 2025+3.0%
Q3 2024Nov 12, 2024 · Before open−4.9%
Q2 2024Aug 12, 2024 · Before open+1.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open+3.6%
Q4 2023Mar 6, 2024 · Before open+1.7%
Q3 2023Nov 9, 2023 · Before open−0.9%
Q2 2023Aug 10, 2023 · Before open−2.3%
Q1 2023May 10, 2023 · Before open+42.6%
Q4 2022Mar 8, 2023 · Before open+0.6%
Q3 2022Nov 9, 2022 · Before open−1.6%
Q2 2022Aug 10, 2022 · Before open−9.9%
Q1 2022May 9, 2022 · Before open−8.3%
Q4 2021Mar 9, 2022 · Before open+5.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck21 slidesSep 2, 2026
Investor Presentation (September 2026)Investor deck22 slidesSeptember 2026
Technical Presentation (June 2026)Technical65 slidesJun 22, 2026
Corporate Update (June 2026)Corporate update48 slidesJune 2026
Investor Presentation (January 2026)Investor deck36 slidesJan 12, 2026
Technical Presentation (December 2025)Technical30 slidesDec 8, 2025
ACR Convergence 2025Conference14 slidesOctober 2025
Investor Presentation (September 2025)Investor deck40 slidesSep 9, 2025
Tandem Meetings 2025Conference14 slidesFebruary 2025
Investor Day (December 2024)Investor day51 slidesDec 10, 2024
All 15 decks
DeckKindSlidesDate
ASH 2024 (American Society of Hematology Annual Meeting)Conference14 slidesDecember 2024
Investor Presentation (April 2024)Investor deck47 slidesApr 16, 2024
Technical Presentation (December 2023)Technical29 slidesDec 11, 2023
Investor Presentation (June 2023)Investor deck61 slidesJune 2023
Investor Presentation (May 2022)Investor deck39 slidesMay 2022

Open Decks

Financings

RaiseDate
Registered direct offering of pre-funded warrants
Announced: about US$30M · US$4 a share · Warrants at US$0.0001
Buyers: Lynx1 Capital Management LP (with an investment fund advised by Lynx1, buying approximately $30 million of pre-funded warrants)
Use of proceeds: Extend cash runway to fund operations into the first quarter of 2027
Dec 26, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Jul 15, 2021.

Price
US$15.00 a share
Shares offered
6,666,667 shares of common stock
Offering size
US$100 million
Underwriters' option
Up to 1,000,000 more shares
Underwriters
MORGAN STANLEY, JEFFERIES, COWEN, BARCLAYS · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 19, 2021
Filed publiclyApr 23, 2021
Amended 4 timesNewest Jul 12, 2021
Shares registered with an exchangeJul 13, 2021
Declared effective by the SECJul 15, 2021
Final prospectus, with the priceJul 19, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 19, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue10.3M2.82M21.0M13.5M10.1M1.08M0
Cost of revenue2.87M4.11M88.2M5.14M3.33M20.6M9.44M
Gross profit7.46M2.82M21.0M13.5M10.1M-19.5M-9.44M
Research and development114.2M107.3M88.2M59.8M45.0M20.6M9.44M
Selling, general and administrative32.0M29.6M25.5M20.4M13.8M6.74M4.77M
Operating income-135.8M-134.8M-93.5M-66.6M-48.6M-26.2M-14.2M
Depreciation and amortization2.90M4.10M5.40M5.10M3.30M1.20M519.0K
EBITDA-132.9M-130.7M-88.1M-61.5M-45.3M-25.0M-13.7M
Interest expense2.77M3.65M3.76M1.18M16.0K00
Income before tax-129.8M-127.5M-89.2M-66.2M-48.6M-26.1M-13.7M
Income tax05.19M-415.0K3.09M-106.0K-552.0K
Net income-129.8M-127.5M-89.2M-66.2M-48.6M-26.1M-13.7M
Earnings per share, basic-1.00-1.14-1.36-2.75-4.17-28.52-0.55
Earnings per share, diluted-1.00-1.14-1.36-2.75-4.17-28.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents152.4M178.7M133.4M120.0M161.4M34.8M41.8M
Short-term investments0111.4M58.7M0
Current assets157.2M292.7M194.2M124.1M165.7M36.4M42.4M
Property, plant and equipment8.71M7.24M7.74M10.1M11.8M5.66M6.41M
Total assets228.8M371.1M272.1M199.1M188.1M49.7M49.4M
Accounts payable1.24M4.28M2.37M2.91M1.76M2.91M1.01M
Current liabilities18.7M36.0M29.8M17.3M21.3M17.4M2.40M
Long-term debt32.5M32.1M26.7M29.3M
Total debt32.5M32.1M30.0M29.3M6.04M7.43M4.89M
Total liabilities105.7M130.1M121.3M99.7M27.3M32.5M6.84M
Shareholders' equity123.1M241.0M150.9M99.4M160.8M-42.5M42.5M
Shares outstanding129.9M112.0M65.6M24.0M23.9M1.14M24.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-135.3M-110.8M-61.4M-66.5M-48.7M-3.02M-12.5M
Capital spending-4.41M-3.83M-3.15M-4.22M-9.94M-4.24M-1.25M
Free cash flow-139.7M-114.6M-64.5M-70.7M-58.6M-7.26M-13.8M
Cash from investing109.4M-52.6M-60.8M-4.22M-9.94M-4.24M-1.25M
Cash from financing-336.0K208.8M135.4M29.4M189.7M288.0K34.8M
Dividends paid00
Share buybacks264.0K326.0K189.7M
Change in cash-26.3M45.3M13.3M-41.4M131.1M-6.97M21.0M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
DEF 14A · Proxy statementOct 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 16, 2026Meeting noticeSEC
8-K · Current reportOct 16, 2026Management or board changeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportSep 30, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeSep 25, 2026Big-stake noticeSEC
8-K · Current reportSep 11, 2026Management or board changeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 2, 2026Management or board changeSEC
8-K · Current reportAug 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportJun 22, 2026Current reportSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
8-K · Current reportMay 22, 2026Meeting outcomeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 7, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 4, 2026Offer documentSEC
10-K · Annual reportMar 4, 2026Annual reportSEC
8-K · Current reportMar 4, 2026ResultsSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
8-K · Current reportNov 26, 2025Management or board changeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 3, 2025Current reportSEC
8-K · Current reportSep 9, 2025Current reportSEC
3 · Initial statement of ownershipAug 22, 2025Insider tradeSEC
8-K · Current reportAug 20, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJul 2, 2025Meeting outcomeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersMay 14, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 14, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 14, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 17, 2025Other filingsSEC
CORRESP · Letter to the SECMar 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 5, 2025Offer documentSEC
S-3 · Registration statementMar 5, 2025Offer documentSEC
10-K · Annual reportMar 5, 2025Annual reportSEC
8-K · Current reportMar 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
8-K · Current reportDec 26, 2024Material contractSEC
424B5 · ProspectusDec 26, 2024Offer documentSEC
8-K · Current reportDec 23, 2024Material contractSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
8-K · Current reportDec 10, 2024Current reportSEC
8-K · Current reportNov 21, 2024FinancingSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 1, 2024Material contractSEC
SC 13G · Big-stake noticeOct 21, 2024Big-stake noticeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
144 · Notice of proposed saleAug 23, 2024Other filingsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
S-8 · Registration statement for employee plansJun 14, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 30, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2024Meeting noticeSEC
SC 13G · Big-stake noticeApr 29, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedApr 23, 2024Big-stake noticeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
424B5 · ProspectusApr 17, 2024Offer documentSEC
8-K · Current reportApr 17, 2024ResultsSEC
FWP · Free writing prospectusApr 17, 2024Offer documentSEC
424B5 · ProspectusApr 16, 2024Offer documentSEC
8-K · Current reportApr 16, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 15, 2024Other filingsSEC
CORRESP · Letter to the SECApr 10, 2024Other filingsSEC
10-K/A · Annual report, amendedApr 10, 2024Annual reportSEC
8-K · Current reportApr 8, 2024Current reportSEC
UPLOAD · Letter from the SECMar 7, 2024Other filingsSEC
S-3 · Registration statementMar 6, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 6, 2024Offer documentSEC
10-K · Annual reportMar 6, 2024Annual reportSEC
8-K · Current reportMar 6, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 2, 2024Insider tradeSEC
8-K · Current reportJan 29, 2024Management or board changeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
8-K · Current reportDec 11, 2023Current reportSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 8, 2023Insider tradeSEC
8-K · Current reportDec 7, 2023Management or board changeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
4 · Change in ownershipJul 24, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 24, 2023Insider tradeSEC
8-K · Current reportJul 24, 2023Management or board changeSEC
8-K · Current reportJun 29, 2023Management or board changeSEC
S-8 · Registration statement for employee plansJun 16, 2023Offer documentSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Management or board changeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
SC 13G · Big-stake noticeJun 12, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJun 8, 2023Big-stake noticeSEC
4 · Change in ownershipJun 6, 2023Insider tradeSEC
SC 13G · Big-stake noticeJun 5, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeJun 5, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJun 5, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2023Insider tradeSEC
SC 13G · Big-stake noticeJun 2, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJun 2, 2023Big-stake noticeSEC
DEFA14A · Additional proxy materialJun 2, 2023Meeting noticeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
8-K · Current reportMay 31, 2023Material contractSEC
8-K · Current reportMay 31, 2023Management or board changeSEC
424B5 · ProspectusMay 26, 2023Offer documentSEC
FWP · Free writing prospectusMay 26, 2023Offer documentSEC
424B5 · ProspectusMay 25, 2023Offer documentSEC
8-K · Current reportMay 17, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveMay 17, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 17, 2023Other filingsSEC
8-K · Current reportMay 16, 2023Current reportSEC
424B5 · ProspectusMay 16, 2023Offer documentSEC
AWMay 16, 2023Other filingsSEC
S-3/A · Registration statement, amendedMay 15, 2023Offer documentSEC
CORRESP · Letter to the SECMay 15, 2023Other filingsSEC
CORRESP · Letter to the SECMay 15, 2023Other filingsSEC
S-3/A · Registration statement, amendedMay 15, 2023Offer documentSEC
S-3/A · Registration statement, amendedMay 15, 2023Offer documentSEC

This page holds 200 of 336 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from TScan Therapeutics, Inc.’s releases · as of Sep 30, 2026

Common shares
63,502,657
Fully diluted
125,749,364

Fully diluted

LineSharesAs of
Common shares63,502,657Sep 30, 2026
Warrants62,246,707Sep 30, 2026

Share count over time

CountShares
Nov 22, 202663,502,657
Sep 30, 202667,779,255

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Lynx1 Capital Management LP8.02M12.6%US$2.52MSep 30, 2026
Bvf Inc5.56M8.8%US$1.75MSep 30, 2026
Boothbay Fund Management, LLC3.4M5.4%US$1.07MSep 30, 2026
Vanguard2.89M4.5%US$910KSep 30, 2026
Baker Bros. Advisors LP2.78M4.4%US$876KSep 30, 2026
Acadian Asset Management LLC1.69M2.7%US$531KSep 30, 2026
Two Sigma1.66M2.6%US$522KSep 30, 2026
Deer Management Co. LLC1.25M2.0%US$386KSep 30, 2026
Renaissance Technologies1.21M1.9%US$380KSep 30, 2026
DC Funds, LP630K0.99%US$198KSep 30, 2026
All 49 holders
HolderSharesOf the companyValueAs of
Geode Capital604K0.95%US$190KSep 30, 2026
BlackRock598K0.94%US$188KSep 30, 2026
Gsa Capital Partners LLP511K0.80%US$161KSep 30, 2026
Marshall Wace, LLP270K0.42%US$83,581Sep 30, 2026
Verdad Advisers, LP227K0.36%US$71,473Sep 30, 2026
State Street207K0.33%US$64,976Sep 30, 2026
Northern Trust139K0.22%US$43,646Sep 30, 2026
UBS108K0.17%US$34,098Sep 30, 2026
Morgan Stanley105K0.16%US$32,943Sep 30, 2026
Letko, Brosseau & Associates Inc95,8750.15%US$30,153Sep 30, 2026
XTX Topco Ltd95,1630.15%US$29,929Sep 30, 2026
Jane Street90,1850.14%US$28,363Sep 30, 2026
Bridgeway Capital Management, LLC75,7070.12%US$23,810Sep 30, 2026
Empowered Funds, LLC69,2070.11%US$21,766Sep 30, 2026
Hrt Financial LP62,6430.10%US$19,000Sep 30, 2026
Kestra Advisory Services, LLC62,5250.10%US$19,664Sep 30, 2026
Goldman Sachs59,6720.09%US$18,767Sep 30, 2026
Citadel51,7560.08%US$16,277Sep 30, 2026
Bank of America37,6240.06%US$11,814Sep 30, 2026
DC Investments Management, LLC35,5630.06%US$11,185Sep 30, 2026
HSBC24,5740.04%US$7,940Sep 30, 2026
R Squared Ltd21,6070.03%US$6,796Sep 30, 2026
Barclays17,0810.03%US$5,372Sep 30, 2026
AQR Capital Management LLC13,8660.02%US$4,361Sep 30, 2026
Ieq Capital, LLC13,7230.02%US$4,316Sep 30, 2026
Pathstone Holdings, LLC10,0000.02%US$3,145Sep 30, 2026
Aries Wealth Management10,0000.02%US$3,145Sep 30, 2026
Global Retirement Partners, LLC10,0000.02%US$3,145Sep 30, 2026
Osaic Holdings, Inc.9,7560.02%US$3,024Sep 30, 2026
Tower Research Capital LLC (TRC)3,955<0.01%US$1,244Sep 30, 2026
Federated Hermes, Inc.3,497<0.01%US$1,100Sep 30, 2026
Fidelity2,000<0.01%US$629Sep 30, 2026
JPMorgan1,715<0.01%US$545Sep 30, 2026
BNP Paribas595<0.01%US$187Sep 30, 2026
SBI Securities Co., Ltd.391<0.01%US$123Sep 30, 2026
Strategic Wealth Partners, Ltd.311<0.01%US$98Sep 30, 2026
RBC87<0.01%Sep 30, 2026
Root Financial Partners, LLC85<0.01%US$27Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.5M2.4%US$1.47MJun 30, 2026
Vanguard Extended Market Index Fund576K0.91%US$564KJun 30, 2026
Fidelity Extended Market Index Fund294K0.46%US$317KMay 31, 2026
iShares Micro-Cap ETF168K0.26%US$164KJun 30, 2026
Fidelity Total Market Index Fund87,5660.14%US$94,571May 31, 2026
Fidelity Series Total Market Index Fund72,9140.11%US$78,747May 31, 2026
Ultra-Small Company Market Fund70,4000.11%US$68,999Jun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund69,4870.11%US$75,046May 31, 2026
Small Cap Equity Fund65,8130.10%US$64,503Jun 30, 2026
NVIT Multi-Manager Small Company Fund44,5000.07%US$43,614Jun 30, 2026
All 20 holders
HolderSharesOf the companyValueAs of
NVIT Small Cap Value Fund39,0000.06%US$38,224Jun 30, 2026
Strategic Advisers U.S. Total Stock Fund29,6120.05%US$31,981May 31, 2026
Vanguard Institutional Total Stock Market Index Fund29,6050.05%US$29,016Jun 30, 2026
Fidelity Nasdaq Composite Index Fund28,7670.05%US$31,068May 31, 2026
Vanguard Balanced Index Fund19,3200.03%US$18,936Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund12,0000.02%US$11,761Jun 30, 2026
1290 VT Micro Cap Portfolio11,2500.02%US$11,026Jun 30, 2026
JNL/DFA U.S. Small Cap Fund3,238<0.01%US$3,174Jun 30, 2026
State Street Balanced Index Fund713<0.01%US$699Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND303<0.01%US$225Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Lynx1 Capital Management LP13.10%20.5MJun 30, 2026Schedule 13G
BVF PARTNERS L P/IL9.99%6.42MJun 30, 2026Schedule 13G
Adage Capital Partners Gp, L.L.C.7.13%3.5MDec 31, 2024Schedule 13G
K2 HealthVentures Equity Trust LLC6.90%3.6MDec 31, 2024Schedule 13G
Readout Capital, LP5.40%3.45MSep 21, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Felix Baker
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past)
Director · Since at least Jul 15, 2021
Julian Baker
Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past)
Director · Since at least Jul 15, 2021
Timothy J Barberich
Other companies: Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Sep 28, 2016 – Jun 20, 2017 · Past); Eledon Pharmaceuticals, Inc. (Director · Sep 16, 2014 – Jun 15, 2016 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past)
Director · Jul 15, 2021 – Dec 18, 2023 · Past
Garry A Nicholson
Other companies: Day One Biopharmaceuticals Inc (Director · Since at least Sep 12, 2022); NextCure, Inc. (Director · Jun 24, 2021 – Jun 22, 2023 · Past); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Turning Point Therapeutics Inc (Director · Jun 2, 2021 – Aug 17, 2022 · Past); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past)
Director · Since at least Jun 12, 2024
Katina Dorton
Other companies: Prelude Therapeutics Incorporated (Director · Since at least Oct 17, 2025); Mallinckrodt Inc (Director · Since at least Feb 2, 2024); Fulcrum Therapeutics, Inc. (Board Member · Since at least Jun 9, 2021); US Ecology Inc (Director · May 26, 2021 – May 2, 2022 · Past); Pandion Therapeutics Inc (Director · Dec 2, 2020 – Apr 1, 2021 · Past)
Director · Since at least Jul 15, 2021
Keith Woods
Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past)
Director · Since at least Dec 6, 2023
Jason Amello
Other companies: Candel Therapeutics, Inc. (Chief Financial Officer · Sep 21, 2022 – Nov 28, 2023 · Past); Acer Therapeutics Inc (Director · Jan 2, 2020 – Mar 14, 2023 · Past); Akebia Therapeutics, Inc. (SVP, CFO & Treasurer · Apr 11, 2019 – Feb 28, 2020 · Past)
Chief Financial Officer · Since at least Jan 29, 2024
Gabriela Gruia
Other companies: Aprea Therapeutics, Inc. (Director · Since at least May 5, 2023); Molecular Templates Inc (Director · Mar 1, 2022 – Sep 27, 2024 · Past)
Director · Since at least Jul 15, 2021
Ann HargravesChief Human Resources Officer · Since at least Nov 5, 2026
Cagan GurerSenior Vice President, Discovery · Since at least Apr 27, 2026
All 25 people
PersonSeat
Caileigh DoughertyAVP, Head of Corporate Communications & Investor Relations · Since at least Sep 2, 2026
Caileigh DoughertyAVPHead of Corporate Communications & Investor Relations · Since at least Jun 22, 2026
Christoph H WestphalDirector · Jul 15, 2021 – Jul 15, 2021 · Past
Chrystal LouisChief Medical Officer · Since at least Apr 22, 2024
Debora BartonChief Medical Officer · Jul 5, 2022 – Jun 13, 2023 · Past
Gavin MacBeathChief Executive Officer · Since at least Jan 20, 2026
Heather SavelleTScan TherapeuticsInc.VP · Dec 26, 2024 – Nov 4, 2026 · Past
Ittai HarelDirector · Jul 15, 2021 – Jun 1, 2022 · Past
Jim MurrayChief Development Operations Officer · Since at least Nov 5, 2024
Leiden DworakSee Remarks · Since at least Jul 21, 2023
Shrikanta ChattopadhyaySenior Vice President, Head of Translational Medicine · Since at least Sep 17, 2025
Stephen CamioloSenior Vice President, Market Access · Mar 27, 2025 – Nov 4, 2026 · Past
TScan TherapeuticsInvestor Relations · Since at least Feb 25, 2026
William DesmaraisChief Business Officer · Jul 15, 2021 – Jul 25, 2022 · Past
Zoran ZdraveskiChief Legal and Strategy Officer and Secretary · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about TScan Therapeutics, Inc.